Preliminary investigations provide indications of the therapeutic benefits of GLP‐1 receptor agonists for people with dementia, eating disorders, psychopharmacologically induced weight gain, depression, anxiety and substance use disorders. Here, GLP1R is linked to depressive symptom measurement.